Unknown

Dataset Information

Double-blind placebo-controlled evaluation of the PROMETA™ protocol for methamphetamine dependence.


ABSTRACT:

Aims

To evaluate the efficacy and safety of the PROMETA™ Protocol for treating methamphetamine dependence.

Design

A double-blind, placebo-controlled 108-day study with random assignment to one of two study conditions: active medication with flumazenil (2 mg infusions on days 1, 2, 3, 22, 23), gabapentin (1200 mg to day 40) and hydroxazine (50 mg to day 10) versus placebo medication (with active hydroxazine only).

Setting

Three substance abuse treatment clinics: two in-patient, one out-patient.

Participants

Treatment-seeking, methamphetamine-dependent adults (n = 120).

Measurements

Primary outcome was percentage of urine samples testing negative for methamphetamine during the trial.

Findings

No statistically significant between-group differences we

SUBMITTER: Ling W 

PROVIDER: S-EPMC4122522 | biostudies-literature | 2012 Feb

REPOSITORIES: biostudies-literature